Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

NCT03315143 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10584

Enrollment

INDUSTRY

Sponsor class

Stopped study terminated due to business decision

Conditions

Heart Failure
Type 2 Diabetes Mellitus
Chronic Kidney Diseases

Interventions

DRUG: Sotagliflozin
DRUG: Placebo

Sponsor

Lexicon Pharmaceuticals

Collaborators

[object Object]